Lilly sues sellers of its unapproved drug retatrutide

On August 12, 2026, Eli Lilly filed six lawsuits against companies it says sold retatrutide, its experimental weight-loss drug. Retatrutide is still in Phase 3 trials, and no regulator anywhere has approved it. Four of the cases covered here are against Legendary Peptides, Lone Star Peptide, Texas Peptides and Striker Pharmacy; the other two named Astra Peptides and Aesthetic Envy Cosmetic Centers. Lilly says the peptide sellers labeled retatrutide "for research use" while really selling it to consumers. These suits are not about compounded copies of Mounjaro or Zepbound. Every claim in them is an allegation, and no court has ruled.

Lilly says Legendary Peptides sold retatrutide labeled for research use, without a prescription, and that the label was a cover for sales to consumers. Because retatrutide is not approved, no version of it can legally be sold to patients outside a clinical trial. The case does not involve Mounjaro, Zepbound, or compounded tirzepatide. The case is at an early stage.

Lone Star Peptide Co. faces the same kind of claim. Lilly says the company sold retatrutide to consumers under a research-use label. Products sold this way have not been checked by the FDA for what is in the vial, how much, or how clean it is. If you have seen retatrutide offered online, this case is a reminder that the drug is still being tested and is not approved for anyone to use outside a trial.

Striker Pharmacy is the only pharmacy among the companies sued. Lilly says it made an unregulated imitation of retatrutide. Compounding pharmacies may make certain drugs under state and federal rules, but retatrutide is not an approved drug, so this case is not about compounding copies of an approved medicine. The suit does not change the rules for compounded semaglutide or tirzepatide.

Texas Peptides Inc. is the fourth seller in this group. As with Legendary and Lone Star, Lilly says it sold retatrutide to consumers while labeling it for research use only. The case is about retatrutide, not about the ingredient supply for compounded tirzepatide.

None of these cases has reached a resolution, and the outcomes will likely take months to play out. They do not change access to any approved GLP-1 drug, including Mounjaro, Zepbound, Ozempic or Wegovy. If you have been offered retatrutide, or are taking a product sold as retatrutide, it is worth telling your prescriber, since the drug is still in trials and products sold online have not been checked by any regulator. This is a legal matter, not a medical one, so any decisions about your treatment should go through your own healthcare provider.

By Amanda Bonello